Little Green Pharma and Cannatrek Announce Transformational Merger.
Little Green Pharma Ltd (ASX: LGP) and Cannatrek Ltd entered into a Scheme Implementation Deed (SID), agreeing for LGP to acquire 100% of Cannatrek’s issued capital. The merger combines two major Australian players in the medicinal cannabis industry. Cannatrek, with its vertically integrated operations, including GMP-certified manufacturing, medical clinics, and distribution, complements LGP’s established European and Australian presence. The merger’s structure includes LGP ordinary shares and contingent value shares for Cannatrek’s shareholders. Upon completion, Cannatrek shareholders will own 60.5% of the combined group, with LGP shareholders holding 39.5%. This deal is a strategic consolidation aimed at creating one of the largest global players in medicinal cannabis, driving growth in the Australian and European markets. The proposed merger aligns with both companies' plans for industry consolidation and enhanced scale to remain competitive in the rapidly growing medicinal cannabis sector.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Little Green Pharma and Cannatrek Announce Transformational Merger.
Little Green Pharma Ltd (ASX: LGP) and Cannatrek Ltd entered into a Scheme Implementation Deed (SID), agreeing for LGP to acquire 100% of Cannatrek’s issued capital. The merger combines two major Australian players in the medicinal cannabis industry. Cannatrek, with its vertically integrated operations, including GMP-certified manufacturing, medical clinics, and distribution, complements LGP’s established European and Australian presence. The merger’s structure includes LGP ordinary shares and contingent value shares for Cannatrek’s shareholders. Upon completion, Cannatrek shareholders will own 60.5% of the combined group, with LGP shareholders holding 39.5%. This deal is a strategic consolidation aimed at creating one of the largest global players in medicinal cannabis, driving growth in the Australian and European markets. The proposed merger aligns with both companies' plans for industry consolidation and enhanced scale to remain competitive in the rapidly growing medicinal cannabis sector.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au